Condition: Prostate Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
This description comes directly from the study's public registry record.
Laura Sena, MD, PhD · 410-502-3825 · laura.sena@jhmi.edu
Kathy Schultz, RN · 410-614-9482 · kschult3@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06059118